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Jim Woodgett was born in rural 
Leicestershire, England and 
now makes his home in Toronto, 
Canada. He earned his PhD under 
the mentorship of Sir Philip Cohen 
in Dundee (1984) and completed 
post-doctoral studies with Tony 
Hunter at the Salk Institute 
(1987). He is currently Director 
of Research at the Samuel 
Lunenfeld Research Institute, 
where his laboratory studies 
the role of abrogated signal 
transduction processes in human 
diseases such as breast and 
colon cancer and diabetes. His 
primary contributions relate to the 
characterization of the biological 
role of protein kinases such as 
GSK-3, protein kinase B/Akt and 
stress-activated protein kinases.
Why did you choose a career in 
medical research? I’d like to say 
it was a conscious decision, but 
when I look back, I was both naïve 
and lucky in the choices I made 
and I certainly didn’t have a plan. 
I was lucky in that I only applied 
to one lab for my PhD studies and 
one lab for my postdoc. It was 
only after the fact that I realized 
how fortunate I was to land in two 
phenomenal laboratories. It was 
also a case of perfect timing when 
I was offered my first independent 
position at the Ludwig Institute 
for Cancer Research, London, 
directed by Mike Waterfield. This 
was a ‘hard money’ position 
and meant I didn’t have to worry 
about grants for at least the first 
few years. In an ideal world, all 
researchers should be given that 
initial ‘grant holiday’ so that they 
can establish themselves. The first 
five years of independence are 
critical and usually set the scene 
for an entire career.
Are you saying you’re against 
research grants? By no means. 
Indeed, having experienced 
both ‘institutional’ and 
‘investigator- initiated’ funding 
systems, I think grant writing 
brings an important level of 
discipline to one’s thinking. You are required to extrapolate 
and explain the rationale for 
your thinking, to justify your 
planned expenditures and to 
make decisions about what 
avenues to pursue. However, the 
granting system also tends to be 
risk- averse and this disadvantages 
young investigators. There again, 
institutional block grants can also 
be limiting as the head count is 
fixed so it is difficult to enable 
successful labs to grow, and 
sometimes this type of funding 
leads to less competitive research.
Is there a best of both worlds? 
I’m a proponent of five year grants 
rather than shorter-term funding 
and I also very much believe in 
the merit of investigator-initiated 
grants rather than large team 
grants. That isn’t to say there isn’t 
a place for the latter, which seem 
to be very much in vogue, but 
the fundamental unit of support 
should be the RO1 type of grant, 
as this allows independence, 
recognition and accountability 
that is more difficult to assess 
in combination grants. In the 
world of genomics and systems 
biology, there is a place for ‘big 
biology’ but it should not be at the 
expense of individual ingenuity.
Have you been ingenious? I 
like to think so, in hindsight. As 
I mentioned, I’ve been lucky. 
My first graduate student, Paul 
Coffer, discovered PKB and, with 
Joe Avruch and John Kyriakis, 
we discovered the family of 
stress- activated protein kinases. 
But my work on an enzyme 
called GSK-3 has been the 
most inspiring for me. I actually 
started to work on it during my 
PhD and have half of my lab 
working on aspects of its biology 
today, 25 years on…. Maintaining 
competitive funding for analysis 
of the same protein for 25 years 
takes some ingenuity! That said, 
it’s a fascinating protein that is 
implicated in a variety of diseases 
such as diabetes, Alzheimers’, 
bipolar disorder and cancer, but 
it’s also got connections to all 
sorts of cellular processes. It’s the 
Tony Soprano of kinases. We’ve 
recently generated floxed alleles 
of the two mouse GSK-3 genes 
and are finding extraordinary effects in every tissue we’ve 
deleted it from so far. 
You’ve recently taken on more 
administration, why? Well, I’ve 
not given up my lab so it’s more 
a question of balance. I think it’s 
critical for heads of departments 
and research directors to maintain 
an active research program to 
ensure they are in tune with the 
issues of their fellow scientists. 
My main reason for accepting 
the position at the Lunenfeld was 
because it’s composed of a truly 
fantastic group of researchers. 
We’re small, just over 30 groups, 
but the impact and output of 
the research of the SLRI is very 
high for its size. This also means 
administration is easier and a 
lot more fun. I’ve benefited from 
superb mentors, including Lou 
Siminovitch, who established the 
SLRI, and I think it’s important 
to pass on that experience. It’s 
also increasingly important to 
communicate what we do in 
biological research to the public 
and politicians. Ultimately, they 
are our paymasters and we 
answer to them. We often hide 
behind our nomenclature and 
technical jargon and presume 
the public understands our aims 
are noble but this a dangerous 
assumption in an age of 30 
second sound bites and “vote 
chasing” politics.
Is this a good time to be doing 
biology? As compared to being an 
SUV salesman? Seriously, I think 
we are in a golden age. The past 
50 years has seen remarkable 
revelations of new knowledge 
and discovery. New industries 
have been established and we 
have learned how to manipulate 
the blueprint of life at the finest 
level. However, the impact of 
this research on our lives has 
been relatively small, compared 
with the industrial revolution, 
for example. The genome 
project coupled with new, highly 
efficient sequencing and mass 
spectrometry methodologies 
and the increasing complexity 
achievable in modeling diseases 
and cell fate will, I think, deliver on 
the promises first imagined during 
the era of recombinant DNA. In 
medical research, there’s also 
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The standard visual system
In the view repeated in every 
textbook, visual coding proceeds 
in three stages. First, light 
is sensed by the retina and 
translated into neuro-electric 
signals. Here, in addition, the 
contrast and brightness of the 
signal are normalized: just as an 
automatic camera adjusts its own 
exposure, the retina maneuvers 
the intensities and contrasts of the 
natural world into a manageable 
operating range.
Second, the retina divides the 
raw visual signal — essentially 
a bitmap of the image — into 
parallel informational streams, 
each encoding a particular aspect 
of the visual input. These are 
reflected in the response to light 
of individual retinal ganglion 
cells, the neurons whose axons 
bundle together to form the 
optic nerve (Figure 1). In the 
standard model, two main types 
of ganglion cell feed the cortical 
pathways for conscious visual 
perception. One is represented 
by a set of cells which, because 
they are numerous, offer the 
brain a high spatial resolution 
and are responsive to standing 
contrast. For historical reasons 
these are usually called PC 
cells, because their signals pass 
through the parvocellular (PC) 
layers of the lateral geniculate 
nucleus (LGN) before reaching 
the visual cortex. A second set of 
cells — MC cells, whose signals 
pass through the magnocellular 
layers of the LGN — are fewer but 
have an enhanced sensitivity to 
images that flash or move. Both 
these cell types have ‘concentric 
center–surround’ organization: 
a supposedly general-purpose 
transmission strategy for encoding 
visual stimuli. For both these 
types of cell, the best stimulus is 
small and more or less circular, 
and the more intense the contrast 
of the stimulus, the more vigorous 
is the response of the cell.
What does the brain do with 
these signals? In the standard 
view, the real business of visual 
processing begins in the primary 
(striate) visual cortex. In the striate 
cortex a major recoding occurs, 
with the dramatic consequence 
that many of the cells become 
sensitive not only to a particular 
patch on the retinal surface, but 
to oriented line segments — to 
edges rather than to spots of 
light. More complex tunings also 
exist, in which the cortical cell 
responds to an edge regardless 
of the edge’s location in space. 
This ‘complex’ transformation 
was initially conceptualized as 
a second step of abstraction, in 
which the cortex’s detection of 
oriented edges was extended 
to the more general case (edge 
sensitivity freed of its association 
with a particular location in 
space). In summary, then: first, the 
retina transmits simple signals to 
the cerebral cortex; second, the 
cortex combines these simple 
signals to detect edges; and third, 
these fundamental building blocks 
are used to delineate the borders 
of objects and create visual 
perceptions.
Though probably intended by no 
one, this view has morphed into 
Essay
Richard H. Masland1 and Paul R. Martin2,3
Vision looms large in neuroscience — it is the subject of a gigantic 
literature and four Nobel prizes — but there is a growing realization that 
there are problems with the textbook explanation of how mammalian 
vision works. Here we will summarize the evidence behind this disquiet. 
In effect, we shall present a portrait of a field that is ‘stuck’. Our initial 
focus, because it is our area of expertise, is on evidence that the early 
steps of mammalian vision are more diverse and more interesting than 
is usually imagined, so that our understanding of the later stages is in 
trouble right from the start. But we will also summarize problems, raised 
by others, with the later stages themselves.
The unsolved mystery of visionan awareness that the pathway 
of discovery to translational 
research to clinical impact is 
bi- directional. We’re picking up far 
more disease-associated changes 
in patients that we can take back 
to genetically tractable models 
to understand causal relationship 
and, ultimately, therapeutic or 
diagnostic utility.
So is the age of discovery over? 
Not by any measure. The primary 
reason we don’t have frequent 
breakthroughs leading to cures 
is because of the limits of current 
understanding. A lot of what 
we do think we know is either 
over-simplified or incomplete. 
A major challenge for a world 
which is impatient and has huge 
expectations for economic and 
health pay-offs and “return on 
investment” is how to balance 
our clear need for new knowledge 
with the need of our society to 
improve quality of life. This is 
exacerbated by the impending 
demographic pressures of 
aging populations and spiraling 
healthcare costs. But the quality 
of translational research is entirely 
dependent on the quality of the 
discoveries being translated and 
it is clear that the most important 
predictor of future impact/utility/
value of research is excellence. 
We must be careful to balance, 
for example, assessment of 
“commercial potential” in relation 
to scientific merit when making 
decisions of research funding. 
We need to better explain our 
work to both the public and to 
decision- makers. I’m optimistic 
that scientists want to get involved 
as demonstrated by our campaign 
that questioned the wisdom 
of vetting financial parameters 
before assessing scientific merit 
(www.sciencefunding.ca) which 
attracted over 1300 signatures. 
If we are to achieve a golden 
age for research, we each have 
the responsibility to explain and 
defend the scientific process that 
has provided so much knowledge 
and value to society to date.
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